USPTO serial 99215725
KROMASURE INSITE
Reviewed by CopyMark Law Group
Status 688Notice of Allowance
- Filing date
- Status date
- Registration date
- —
- Examiner
- BAYLISS, HUNTER A
- Law office
- INTENT TO USE SECTION
What this means
The USPTO has issued a Notice of Allowance. To complete registration you generally need to file a Statement of Use or an extension request before the deadline.
Need help with KROMASURE INSITE?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Get help with this Notice of Allowance, set up monitoring, or talk with CopyMark.
Get Attorney Assistance for just $1,844*
Plus Government fees of $900
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
LONGMONT, CO, US
LONGMONT, CO, US
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Amanda H. Wilcox
Amanda H. Wilcox Taft Stettinius & Hollister LLP200 Public Square, Suite 3500Cleveland, OH 44114United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | Assays and reagents for use in genetic research; Assays for research purposes; Diagnostic preparations for scientific or research use; Diagnostic preparations for scientific use; Diagnostic reagents for scientific or research use; Diagnostic reagents for scientific use; Nucleic acid isolation and purification kit consisting primarily of reagents and magnetic beads for scientific research purposes; Reagent kits comprising generic DNA circle, DNA primers, polymerase and buffers for use as reagents for scientific and research use in biotechnology fields; Testing kits containing peptide substrates used in analyzing and detecting certain toxins for research purposes | ACTIVE | — |
| 005 | Cell growth media for growing cells for medical or clinical use; Cells for medical or clinical use; Cells for medical use; Clinical medical reagents; Diagnostic kits comprised of medical diagnostic reagents and assays for testing of bodily fluids for use in disease detection for medical purposes; Diagnostic kits consisting primarily of monoclonal antibodies, buffers, and reagents for use in disease testing; Immunoassay reagents for medical use; Culture media for cultivating human blood cells for diagnosing disease for medical purposes; Solutions for medical and clinical use in storing and treating cells, blood and blood components; Stem cells for medical or veterinary use; Stem cells for medical purposes; Diagnostic kits consisting primarily of monoclonal antibodies, buffers, and reagents to monitor toxicity of drugs for medical purposes; Diagnostic preparations for medical purposes used by clinical or medical laboratories; Diagnostic reagents for medical purposes used by clinical or medical laboratories; Testing kits containing peptide substrates used in analyzing and detecting certain toxins used by clinical or medical laboratories | ACTIVE | — |
| 010 | Diagnostic kits consisting primarily of probes, buffers and reagents for use in microbial testing | ACTIVE | — |
| 035 | Business consulting and management in the field of clinical trials, namely, clinical data and regulatory submission management on behalf of medical, biopharmaceutical and biotechnology companies to assist them with clinical research, clinical trials and applications for drug approval; Business consulting and management in the field of clinical trials, namely, providing information management services | ACTIVE | — |
| 042 | Custom design and development of chemical reagents and biochemical assays; DNA analysis services for scientific research purposes; DNA screening for scientific research purposes; Medical and scientific research in the field of cancer treatment and diagnosis; Medical and scientific research, namely, conducting clinical trials for others; Medical research; Medical research in the field of oncology; Medical research services; Scientific research; Scientific research and development; Scientific research consulting; Scientific research in the field of genetics and genetic engineering; Genetic testing for scientific research purposes; Providing medical and scientific research information in the field of pharmaceuticals and clinical trials; Providing medical and scientific research information in the fields of pharmaceuticals and genetics; Scientific research for medical purposes in the area of cancerous diseases | ACTIVE | — |
| 044 | DNA screening for medical purposes | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Kromatid Inc.
- Other trademarks owned by Kromatid Inc.
- Other trademarks in Class 001
- Other trademarks in Class 005
- Other trademarks in Class 010
- Other trademarks in Class 035
- Other trademarks in Class 042
- Other trademarks in Class 044
- Similar marks named KROMASURE INSITE
- Prosecution event NOAM explained
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Sep 29, 2026 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Aug 4, 2026 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Aug 4, 2026 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Jul 29, 2026 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Jul 6, 2026 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Apr 27, 2026 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Apr 27, 2026 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Apr 27, 2026 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jan 30, 2026 | XELG | APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED | — |
| Jan 30, 2026 | XELR | APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED | — |
| Oct 31, 2025 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Oct 31, 2025 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Oct 31, 2025 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Oct 23, 2025 | DOCK | ASSIGNED TO EXAMINER | — |
| Oct 17, 2025 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Jun 3, 2025 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Jun 3, 2025 | NWAP | NEW APPLICATION ENTERED | — |